Benchmark Financial Wealth Advisors LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Benchmark Financial Wealth Advisors LLC increased its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 11.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,136 shares of the medical research company’s stock after acquiring an additional 119 shares during the period. Benchmark Financial Wealth Advisors LLC’s holdings in Amgen were worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Southland Equity Partners LLC grew its holdings in shares of Amgen by 2.3% during the fourth quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after buying an additional 34 shares during the last quarter. Acropolis Investment Management LLC lifted its position in Amgen by 3.5% in the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after purchasing an additional 34 shares during the period. Opal Wealth Advisors LLC lifted its position in Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 34 shares during the period. FORVIS Wealth Advisors LLC lifted its position in Amgen by 1.4% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 35 shares during the period. Finally, Evanson Asset Management LLC lifted its position in Amgen by 2.1% in the fourth quarter. Evanson Asset Management LLC now owns 1,666 shares of the medical research company’s stock valued at $480,000 after purchasing an additional 35 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and lifted their price target for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. Leerink Partnrs downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Morgan Stanley reduced their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Finally, UBS Group reduced their price target on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $295.30.

Check Out Our Latest Research Report on AMGN

Amgen Stock Down 2.4 %

Shares of NASDAQ:AMGN traded down $6.83 during midday trading on Tuesday, hitting $276.21. 2,220,460 shares of the company’s stock traded hands, compared to its average volume of 3,009,285. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market cap of $148.03 billion, a PE ratio of 22.38, a P/E/G ratio of 2.69 and a beta of 0.58. The firm’s fifty day moving average price is $288.67 and its two-hundred day moving average price is $281.34.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter in the previous year, the business posted $4.09 EPS. The firm’s revenue was up 19.8% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.26%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.